International infant formula manufacturers are adjusting their business practices in China having been found guilty of price fixing. Multina...
There were, despite continued economic uncertainty in many Western markets and concerns over slowing growth in the East, signs that M&A acti...
Heinz stunned the global food industry with news it had agreed to a US$28bn takeover offer from Warren Buffett's Berkshire Hathaway fund and private-equity firm 3G Capital - purported to be the largest-ever deal in the sector. Dean Best looks at what could lie ahead for the US food giant.
Nestle's health science division has continued to motor below the radar in the first half of 2012 and the group is confident of a bright future for the unit.
Nestle has said innovation is key to growth in developed markets where the company says achieving higher sales is "no walk in the park".
Last week started with a bang, when on Monday morning (23 April) Nestle announced that it had beaten off competition from the likes of Danone to secure the baby food business of US pharmaceuticals group Pfizer.
Nestle is witnessing dynamic growth in China thanks to a combination of M&A and organic growth. As we discovered in part one of this two part interview, regional chief Roland Decorvet attributes much of this success to Nestle's use of local and global brands. But operating in China is not without its challenges. Katy Askew caught up with Decorvet to find out more about why he believes Nestle is best-placed of all the multinationals to succeed in China.
The potential offered by the Chinese market is nothing new. And nor is Nestle's presence in the country. The world's largest food group started trading in Hong Kong in 1874 and opened its first sales office on the mainland in 1908. In recent years Nestle has stepped up the pace with the development of a distinctive model it believes will drive expansion. In part one of the just-food interview, Roland Decorvet, chairman and CEO of Nestle Greater China, spoke to Katy Askew about the company's strategy in the market.
South African pharma group Aspen Holdings has snapped up 50% of New Zealand infant formula producer New Zealand New Milk.
Nestle has sold baby food brands Alete and Milasan to German investment firm BWK for an undisclosed sum.
South African pharmaceutical group Aspen Pharmacare has acquired Nestle's infant milk factory in Mexico and licences for some of its brands in Latin America.
Aspen Pharmacare is to acquire the Pfizer infant nutrition businesses in Australia and southern Africa after a deal with Nestle worth US$215m.
Nestle will sell Pfizer's Mexican business to settle competition issues in the market arising from its deal last year to buy the pharmaceutical giant's infant nutrition operations worldwide.
Mead Johnson has dismissed any suggestions Nestle will prove to be formidable competition in China following the Swiss food group's acquisition of Pfizer's baby food business.
US infant nutrition group Mead Johnson says it is facing tough comparables this year due to pricing problems in China in 2012 but said it expects a rebound in growth in the back half of 2013.
Swiss food giant Nestle has said it hopes to "come back strongly" in infant nutrition in the US, where it believes a "postponed birth spurt" could drive growth of the category.
One story has dominated the industry headlines last week - the deepening and widening horse meat contamination, which has now taken in household brand Findus and a supplier in France. Beyond the debate over food standards and the scrutiny of the supply chain, Dairy Crest admitted it was struggling to find suitable M&A targets, Marks and Spencer said its Simply Food ambitions could lead them beyond France and further into Europe, while Kellogg insisted it was seeing improvement in its business in the region.
Few stories in recent months have caused as much comment as the horse meat scandal, which last week deepened with the news Findus lasagne sold in the UK contained the ingredient. Elsewhere, Dairy Crest said potential takeover targets wanted too much money, Nestle found another country looking at the implications of its Pfizer infant formula acquisition and Kraft Foods Group went to court over the Cracker Barrel trademark.
South Africa's Competition Commission will recommend the Competition Tribunal approve the South African leg of Nestle's global acquisition of Pfizer Nutrition, with a number of conditions, at a hearing tomorrow (6 February).
Nestle has declined to comment on a report claiming it could sell US$1bn of assets in Latin America in order to secure final regulatory approvals for its Pfizer nutrition unit acquisition.
Nestle's acquisition of Pfizer's infant nutrition has been blocked by Mexico's anti-trust authority and had conditions attached to it by Australia's competition regulator.
Unilever CEO Paul Polman is one of the most prominent advocates of companies pursuing an agenda of sustainability and this week he outlined the company's progress. Meanwhile, Wal-Mart Stores was forced to react to claims of bribery in its Mexican operations and Nestle's acquisition of Pfizer's baby food business was scrutinised by analysts. The investment community also had a raft of first-quarter results to get their teeth into, with Kellogg, PepsiCo, Premier Foods plc and Hershey among the companies reporting.
Allegations of bribery at Wal-Mart Stores' Mexican arm grabbed the headlines at the start of the week, rocking the world's largest retailer. Nestle, the world's largest food manufacturer, made waves of its own with its US$11.9bn deal to buy Pfizer's baby food business. The week also saw a raft of first-quarter results and the announcement of the latest results from Unilever's Sustainable Living Plan, a programme to reduce its impact on the environment. We met Unilever CEO Paul Polman to discuss the company's progress.
Heinz has signed an investment agreement with the government of the Sanshui district in the Chinese city of Foshan for the construction of a baby food manufacturing base.
Nestle has agreed a deal to acquire the infant nutrition business of US pharmaceuticals group Pfizer for US$11.85bn.
A raft of first-quarter results stories this week from the likes of Danone and Nestle, and full-year results from Tesco have kept analysts busy.
Tesco's plan to win back UK consumers understandably grabbed the headlines this week but there was plenty to analyse elsewhere. Nestle featured in the latest M&A speculation, with rumours that a deal to buy Pfizer's baby food unit was near and talk that it could sell its ice cream business in Australia. The food giant also kicked off the run of results announcements for the first quarter and joined Danone in outlining the challenges of operating in weak developed markets. Click on the headlines for more.
French food giant Danone has reportedly raised its offer for the infant nutrition business of US pharmaceutical group Pfizer.
US pharmaceutical group Pfizer has insisted it will get maximum value for its shareholders out of any move to separate its infant nutrition business.
Nestle is the most likely candidate to acquire the infant nutrition arm of US pharmaceutical group Pfizer, analysts have suggested.
- US food next wave on display at Winter Fancy Food
- Does Kraft Heinz want to swallow Unilever whole?
- Focus: Nestle CEO plan to balance sales, earnings
- Comment: Meal kits in US - don't believe the hype
- Wessanen eyes growth in "resurgent" organic market
- Unilever launches operational review
- Kraft Heinz pulls Unilever bid
- General Mills issues profit warning
- Kerry operating earnings strengthen on slow sales
- Glanbia focuses on nutrition with Irish dairy spin